CCM
OTLK icon

Crew Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Crew Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$7.88K – 124
2023
Q4 		$7.88K Buy
1,000
+500
+100% +$4.23K 0.01% 88
2023
Q3 		$2.21K Hold
500
– – ﹤0.01% 74
2023
Q2 		$17.4K Hold
500
– – 0.02% 85
2023
Q1 		$10.9K Hold
500
– – 0.02% 87
2022
Q4 		$10.8K Hold
500
– – 0.02% 90
2022
Q3 		$12K Hold
500
– – 0.02% 90
2022
Q2 		$10K Hold
500
– – 0.01% 91
2022
Q1 		$18K Buy
+500
New +$15.6K 0.02% 111

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Crew Capital Management's OTLK Position: Q1 2024 in Review

Crew Capital Management sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 1,000 shares — an estimated $7.88K sold.

Crew Capital Management first reported a position in OTLK in Q1 2022 and held it in 8 quarters. The position peaked at $18K in Q1 2022. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Crew Capital Management reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Crew Capital Management sold 1,000 Outlook Therapeutics shares in Q1 2024, an estimated $7.88K.
  • Crew Capital Management first reported a position in Outlook Therapeutics in Q1 2022 and held it in 8 quarters.
  • Crew Capital Management's Outlook Therapeutics position peaked at $18K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Crew Capital Management's 13F filing for Q1 2024, filed 29 Apr 2024.